Cerimon Pharmaceuticals

company

About

Cerimon Pharmaceuticals develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains.

  • 11 - 50

Details

Last Funding Type
Series A
Last Funding Money Raised
$70M
Industries
Biotechnology,Health Care,Pharmaceutical,Therapeutics
Founded date
Jan 1, 2004
Number Of Employee
11 - 50
Operating Status
Active

Cerimon Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for autoimmune diseases, inflammation, and pains in the United States and Europe. It develops Simulect, a monoclonal antibody for the treatment of moderate-to-severe and steroid-refractory ulcerative colitis; diclofenac sodium, a non-steroidal anti-inflammatory drug that are used to treat various pains, including pain due to musculoskeletal injuries and lower back pain; and topical diclofenac sodium patch products. Cerimon Pharmaceuticals, Inc. was founded in 2004 and is headquartered in South San Francisco, California.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$70M
Cerimon Pharmaceuticals has raised a total of $70M in funding over 2 rounds. Their latest funding was raised on Oct 26, 2005 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Oct 26, 2005 Series A $70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
Cerimon Pharmaceuticals is funded by 1 investors. Phase4 Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
Phase4 Ventures Series A